5-methoxytryptamine has been researched along with Parkinson Disease in 2 studies
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.
5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has been shown to prevent the progressive degeneration produced by neurotoxins employed in experimental models to mimic the degenerative events in various neuropsychiatric disease states." | 2.43 | The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. ( Willis, GL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willis, GL | 2 |
| Kennedy, GA | 1 |
2 reviews available for 5-methoxytryptamine and Parkinson Disease
| Article | Year |
|---|---|
The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dose-Response | 2004 |
The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Melato | 2005 |